ஜர்னல் ஆஃப் குரோமடோகிராபி & பிரிப்பு நுட்பங்கள்
திறந்த அணுகல்

சுருக்கம்

Stability Indicating HPLC Method for Simultaneous Estimation of Entacapone, Levodopa and Carbidopa in Pharmaceutical Formulation

Bhatnagar P, Vyas D, Sinha SK and Chakrabarti T

In pharmaceutical industry, researchers aim at catering to the need of robust analytical methods for analysis of generic drug products. The paper deals with the pharmaceutical formulation - Entacapone, Levodopa and Carbidopa tablets for the treatment of Parkinson’s disease. The paper presents a simple and efficient stability indicating HPLCmethod that has been developed in a multi component drug formulation for simultaneous estimation of Entacapone, Levodopa and Carbidopa in presence of their related impurities. This HPLC method uses ‘Cosmosil PE 150 × 4.6 mm, 5 μ’ HPLC column, phosphate buffer pH 2.5 and Methanol as mobile phase in gradient mode with UV detection at 280 nm. The method was validated and found to be precise, robust, accurate, linear (in range 0.05 to 0.15 mg/ml, 0.012 to 0.15 mg/ml and 0.003 to 0.038 mg/ml of Entacapone, Levodopa and Carbidopa respectively), and specific for 15 known impurities ensuring suitability of the method for quantitative determination of Entacapone, Levodopa and Carbidopa.